Sareum Holdings PLC

("Sareum" or the "Company")

Update on SRA737

Cambridge, UK, 31 December 2024- Sareum Holdings plc (AIM: SAR), a biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer, today provides an update on the status of SRA737.

SRA737 is a clinical-stage oral, selective Checkpoint kinase 1 inhibitor that targets cancer cell replication and DNA damage repair mechanisms. It was discovered and initially developed by scientists at The Institute of Cancer Research in collaboration with Sareum, with funding from Sareum and Cancer Research UK. In January 2024, Sareum announced that its co-development partner the CRT Pioneer Fund ("CPF"), had entered into a development and commercialisation license for SRA737 with a private biopharma company in the US.

Sareum has been notified by CPF that it received notice of termination of the SRA737 licence from the US-based licensee on 26 December 2024. The notice period runs for 90 days and Sareum will meet the team from CPF to discuss what steps, if any, are appropriate to seek an alternative licensee once the asset has returned to CPF on 27th March 2025.

Stephen Parker, Executive Chairman of Sareum, commented: "Although clearly disappointed by this outcome, Sareum is now fully focused on its pipeline of TYK2/JAK1 inhibitors and our priority is to drive our lead programme, SDC-1801, towards Phase 2 development."

CPF acquired worldwide commercial rights to the programme in 2013 as part of a co-development agreement with Sareum. SRA737 was licensed by CPF to Sierra Oncology in September 2016. Sierra progressed SRA737 through Phase 1/2 clinical development and, at the 2019 ASCO Annual meeting, reported positive preliminary efficacy and safety data from two clinical trials evaluating SRA737 as a monotherapy and in combination with chemotherapy. Sierra did not progress the asset beyond the Phase 1/2 clinical trial and was acquired by GSK in 2022, with rights returned to CPF in January 2023.

For further information, please contact:

Sareum Holdings plc
Stephen Parker, Executive Chairman | 01223 497700
ir@sareum.co.uk

Strand Hanson Limited (Nominated Adviser)
James Dance / James Bellman | 020 7409 3494

Oberon Capital (Joint Broker)
Mike Seabrook / Nick Lovering | 0203 179 5300

Hybridan LLP (Joint Broker)
Claire Noyce | 020 3764 2341

ICR Healthcare (Financial PR)
Jessica Hodgson / Davide Salvi | 020 3709 5700

About Sareum

Sareum (AIM: SAR) is a biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer.

The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1SDC-1801 is a potential treatment for a range of autoimmune diseases, including psoriasis, and has completed Phase 1 clinical development.

Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy.

Sareum Holdings plc is based in Cambridge, UK, and is quoted on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com.

communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

UPDFBLLXZLLFFBX